The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.
Name: Dasatinib
Allocation: N/A
Single Group Assignment
There are 3 SNPs
- Patients with mutation of T315I, F317L, V299L. --- T315I --- --- F317L ---
- Patients with mutation of T315I, F317L, V299L. --- T315I ---
- Patients with mutation of T315I, F317L, V299L. --- T315I --- --- F317L --- --- V299L ---